5.8 Pharmacopoeial Harmonisation - ((hot))

For multinational pharmaceutical companies, this fragmentation results in "multiple testing." A manufacturer exporting a product to the US, Europe, and Japan might have to test the same batch three different ways to satisfy three different monographs. This redundancy increases manufacturing costs, complicates supply chains, and wastes valuable laboratory resources. It also creates regulatory hurdles during inspections, as companies must justify why they used one method over another.

Beyond methods, has harmonized dozens of excipient monographs. Examples include Benzalkonium Chloride solution, Magnesium Stearate, Lactose Monohydrate, and Polysorbate 80. This means a manufacturer buying Magnesium Stearate from a supplier in India can test it using a USP method and submit the same data to the Japanese PMDA (Pharmaceuticals and Medical Devices Agency). 5.8 pharmacopoeial harmonisation

Specifically, defines the legal and procedural status of harmonized pharmacopoeial standards. It clearly states that for any general method or excipient monograph that has been harmonized by the PDG, the three pharmacopoeias agree that the tests and acceptance criteria are interchangeable . Specifically, defines the legal and procedural status of

The group focuses on harmonizing excipient monographs and general chapters (test methods). For multinational pharmaceutical companies